Who is sponsoring NCT02218177?

NCT02218177 is sponsored by University Health Network, Toronto.

What condition does NCT02218177 study?

NCT02218177 studies Age Related Macular Degeneration.

What drugs are being tested in NCT02218177?

Interventions: Aflibercept, Ranibizumab, Combination Photodynamic Therapy.

What is the status of NCT02218177?

NCT02218177 is currently COMPLETED.

Last reviewed 2018-10-09 · How we verify

Neovascular Age-related Macular Degeneration: Intraocular Inflammatory Cytokines in the Non-responder to Ranibizumab Treatment

NCT02218177 COMPLETED

The purpose of this study is to evaluate the level of cytokines (which are small proteins important in cell signalling) in eye fluid (aqueous humour) in patients with wet age related macular degeneration patients who have been treated with an injection in the eye (intravitreal injection) with a drug called ranibizumab. The level of cytokines will be compared between patients who have a good response to ranibizumab treatment and patients who are non-responsive to ranibizumab and need other forms of therapy. This knowledge will help for the future treatment and to potentially develop new medication for wet age-related macular degeneration.

Details

Lead sponsor	University Health Network, Toronto
Status	COMPLETED
Enrolment	30
Start date	2014-08
Completion	2016-12

Conditions

Age Related Macular Degeneration

Interventions

Aflibercept
Ranibizumab
Combination Photodynamic Therapy

Primary outcomes

Aqueous Humour Cytokine Levels — At time of Intravitreal Injection

Countries

Canada